Global Partnerships Nabriva has a history of regional distribution partnerships for Xenleta and Contepo and has recently divested Contepo North American rights. This creates opportunities to pursue new licensing or co promotion deals to broaden Xenleta and Contepo footprints across Europe, Asia Pacific, and other markets. The US NDA for Contepo and Xenleta commercial presence make it attractive for partners with established sales and regulatory capabilities.

Contepo Focus Contepo is being developed for complicated urinary tract infections with an NDA filed in the United States, signaling a differentiated first in class option. This sets up a strong case for strategic alliances or licensing with a partner that can fund late stage development, manage regulatory work, and execute a field sales plan focused on hospitals and urology.

Xenleta Growth Xenleta has an FDA approved oral and IV formulation and has previously worked with regional distributors. The opportunity is to re engage distribution partners or find new regional collaborators to broaden access in key markets where antibiotic demand remains high.

Market Targeting The primary sales focus should target hospitals and ID and urology specialists, with emphasis on formulary access, reimbursement pathways, and hospital procurement channels. Partnering with established distributors or co marketing teams can accelerate uptake given the lean internal commercial footprint.

Lean Advantage The company operates with a lean team and moderate revenue, which makes strategic partnerships and revenue sharing arrangements attractive to scale globally without a heavy internal sales build. Explore licensing or co development deals, royalties, and milestone based structures with larger pharma partners to expand reach.